Pancreatic Cancer Research

ResearcherFukushima Medical UniversityActive in the last 2 years

Rei Suzuki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4049-0484; OpenAlex author ID A5055817781. Sources: OpenAlex.

Their work

Papers
26 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
71
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 5 papers · 2023: 2 papers · 2024: none · 2025: 5 papers

Papers 26

  1. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  2. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  3. Prediction model for mutation detection via circulating tumor DNA analysis in pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.09.003↗
  4. Prediction System for KRAS Mutation Detection in Circulating Tumor DNA in Unresectable Pancreatic Cancer. First author DOI 10.21873/anticanres.17751↗
  5. Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. Co-author DOI 10.5387/fms.24-00011↗
  6. Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from … First author DOI 10.1186/s12885-023-10781-x↗
  7. A multicenter comparative study of endoscopic ultrasound-guided fine-needle biopsy using a Franseen needle versus conventional endoscopic ultrasound-guided fin… Co-author DOI 10.5946/ce.2022.019↗
  8. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  9. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  10. The Complement C3a-C3a Receptor Axis Regulates Epithelial-to-Mesenchymal Transition by Activating the ERK Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15587↗
  11. Intracellular C3 Modulates EMT via the Akt/Smad Pathway in Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.16081↗
  12. Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer. Co-author DOI 10.5387/fms.2021-32↗
  13. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. Co-author DOI 10.1186/s12885-021-09069-9↗
  14. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospectiv… First author DOI 10.1007/s00280-019-03983-3↗
  15. An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.9626↗
  16. Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.23377↗
  17. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy. First author DOI 10.3892/mco.2018.1696↗
  18. Endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Co-author DOI 10.5387/fms.2018-14↗
  19. Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer. Co-author DOI 10.5387/fms.2017-04↗
  20. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2016.09.003↗
  21. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1078-0432.ccr-15-2780↗
  22. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Co-author DOI 10.3892/ol.2016.4381↗
  23. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Co-author DOI 10.1038/labinvest.2014.143↗
  24. Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Co-author PMID 25202045↗
  25. [Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience]. Co-author PMID 24393954↗
  26. ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-g… Co-author DOI 10.1007/s10147-011-0197-3↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromasa Ohira · 18 shared papers, 2011–2025 · strength 2.15
  2. Mitsuru Sugimoto · 17 shared papers, 2016–2025 · strength 2.13
  3. Tadayuki J. Takagi · 17 shared papers, 2011–2025 · strength 1.90
  4. Hiroyuki Asama · 12 shared papers, 2016–2025 · strength 1.58
  5. Hiroki Irie · 10 shared papers, 2018–2025 · strength 1.31
  6. Hiroshi Shimizu · 3 shared papers, 2025 · strength 0.71
  7. Kentaro Sato · 3 shared papers, 2025 · strength 0.71
  8. Kunihiro Tsuji · 4 shared papers, 2022–2025 · strength 0.54
  9. Satoshi Kobayashi · 4 shared papers, 2022–2025 · strength 0.54
  10. Naohiro Okano · 4 shared papers, 2022–2025 · strength 0.54
  11. Junji Furuse · 4 shared papers, 2022–2025 · strength 0.54
  12. Makoto Ueno · 4 shared papers, 2022–2025 · strength 0.54
  13. Rei Ohira · 2 shared papers, 2025 · strength 0.49
  14. Yuichi Waragai · 5 shared papers, 2016–2025 · strength 0.46
  15. Akinori Asagi · 3 shared papers, 2022–2025 · strength 0.43
  16. Masafumi Ikeda · 3 shared papers, 2022–2025 · strength 0.43
  17. Hiroaki Nagano · 3 shared papers, 2022–2025 · strength 0.43
  18. Yasuyuki Kawamoto · 3 shared papers, 2022–2025 · strength 0.43
  19. Chigusa Morizane · 3 shared papers, 2022–2025 · strength 0.43
  20. Yohei Kitano · 3 shared papers, 2022–2025 · strength 0.43
  21. Kumiko Umemoto · 3 shared papers, 2022–2025 · strength 0.43
  22. Hiroshi Imaoka · 3 shared papers, 2022–2025 · strength 0.43
  23. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  24. Takeshi Terashima · 2 shared papers, 2025 · strength 0.32
  25. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.